期刊
IMMUNOTHERAPY
卷 3, 期 3, 页码 371-380出版社
FUTURE MEDICINE LTD
DOI: 10.2217/IMT.11.4
关键词
antigen-based selection; B lymphocyte; biotin-avidin interaction; electrical pulse; hybridoma cell; immunoglobulin receptor; monoclonal antibody; myeloma cell; selective fusion
类别
资金
- Ministry of Education, Science, Sports and Culture of Japan
- Ministry of Economy, Trade and Industry
- Japan Science and Technology Agency
- Research Foundation for Electrotechnology of Chubu
- Iketani Science and Technology foundation
- Iwtani Naoji Foundation
Hybridoma technology features effective usage of innate functions of both immune cells and cancers, allowing production of hybridoma cells, which continuously generate monoclonal antibodies specific to antigens of interest. For standard generation of hybridoma cells, B lymphocytes must be somatically fused with myeloma cells using various technologies. However, the methods generally do not necessarily result in selective fusion of target B lymphocytes with myeloma cells. To overcome this problem, we have developed a new hybridoma technology that involves preselection of B lymphocytes with target antigens based on immunoglobulin receptors and selective fusion of B cell myeloma cell complexes with electrical pulses. The advanced methodology, termed B-cell targeting, multitargeting and stereospecific targeting, may be applicable to simultaneous production of monoclonal antibodies, selective production of stereospecific monoclonal antibodies, and also to efficient generation of human monoclonal antibodies for clinical purposes.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据